Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series

Abstract Objectives To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody. Methods Nine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE...

Full description

Saved in:
Bibliographic Details
Published inRheumatology (Oxford, England) Vol. 61; no. 6; pp. 2625 - 2630
Main Authors Zhang, Hao, Sun, Yue, Liu, Honglei, Cheng, Xiaobing, Ye, Junna, Hu, Qiongyi, Jia, Jinchao, Wang, Mengyan, Liu, Tingting, Zhou, Zhuochao, Yang, Chengde, Chi, Huihui, Teng, Jialin, Su, Yutong
Format Journal Article
LanguageEnglish
Published England Oxford University Press 30.05.2022
Subjects
Online AccessGet full text
ISSN1462-0324
1462-0332
1462-0332
DOI10.1093/rheumatology/keab629

Cover

Abstract Abstract Objectives To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody. Methods Nine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE therapy at Ruijin Hospital from October 2017 to December 2020. The clinical manifestations, laboratory tests, chest CT and lower extremity MRI images before and after PE therapy were compared. The treatment response was evaluated by the 2016 ACR/EULAR myositis response criteria. Results A total of 88.9% (8/9) of subjects had achieved improvement by 3 weeks after PE therapy, with 55.6% (5/9) minimal improvement and 33.3% (3/9) moderate improvement. There were statistically significant improvements between baseline and after PE therapy at 3 weeks on the core set measures: physician global activity, patient global activity, HAQ, manual muscle testing (MMT), extramuscular disease activity, and muscle enzymes activity including creatine kinase (CK), lactate dehydrogenase (LDH), aspartate transaminase (AST), except for alanine transaminase (ALT). Moreover, the chest CT showed regression of ground glass opacities and irregular linear opacities after PE therapy in four patients with interstitial lung disease. The MRI images of lower extremity in four patients showed reduction of muscle oedema after the therapy. Conclusion PE therapy is effective for refractory IIM patients with positive anti-SRP antibody. It should be considered as an alternative treatment for those patients who are resistant to the combined therapy of glucocorticoids and immunosuppressive agents.
AbstractList To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody.OBJECTIVESTo explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody.Nine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE therapy at Ruijin Hospital from October 2017 to December 2020. The clinical manifestations, laboratory tests, chest CT and lower extremity MRI images before and after PE therapy were compared. The treatment response was evaluated by the 2016 ACR/EULAR myositis response criteria.METHODSNine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE therapy at Ruijin Hospital from October 2017 to December 2020. The clinical manifestations, laboratory tests, chest CT and lower extremity MRI images before and after PE therapy were compared. The treatment response was evaluated by the 2016 ACR/EULAR myositis response criteria.A total of 88.9% (8/9) of subjects had achieved improvement by 3 weeks after PE therapy, with 55.6% (5/9) minimal improvement and 33.3% (3/9) moderate improvement. There were statistically significant improvements between baseline and after PE therapy at 3 weeks on the core set measures: physician global activity, patient global activity, HAQ, manual muscle testing (MMT), extramuscular disease activity, and muscle enzymes activity including creatine kinase (CK), lactate dehydrogenase (LDH), aspartate transaminase (AST), except for alanine transaminase (ALT). Moreover, the chest CT showed regression of ground glass opacities and irregular linear opacities after PE therapy in four patients with interstitial lung disease. The MRI images of lower extremity in four patients showed reduction of muscle oedema after the therapy.RESULTSA total of 88.9% (8/9) of subjects had achieved improvement by 3 weeks after PE therapy, with 55.6% (5/9) minimal improvement and 33.3% (3/9) moderate improvement. There were statistically significant improvements between baseline and after PE therapy at 3 weeks on the core set measures: physician global activity, patient global activity, HAQ, manual muscle testing (MMT), extramuscular disease activity, and muscle enzymes activity including creatine kinase (CK), lactate dehydrogenase (LDH), aspartate transaminase (AST), except for alanine transaminase (ALT). Moreover, the chest CT showed regression of ground glass opacities and irregular linear opacities after PE therapy in four patients with interstitial lung disease. The MRI images of lower extremity in four patients showed reduction of muscle oedema after the therapy.PE therapy is effective for refractory IIM patients with positive anti-SRP antibody. It should be considered as an alternative treatment for those patients who are resistant to the combined therapy of glucocorticoids and immunosuppressive agents.CONCLUSIONPE therapy is effective for refractory IIM patients with positive anti-SRP antibody. It should be considered as an alternative treatment for those patients who are resistant to the combined therapy of glucocorticoids and immunosuppressive agents.
Abstract Objectives To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody. Methods Nine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE therapy at Ruijin Hospital from October 2017 to December 2020. The clinical manifestations, laboratory tests, chest CT and lower extremity MRI images before and after PE therapy were compared. The treatment response was evaluated by the 2016 ACR/EULAR myositis response criteria. Results A total of 88.9% (8/9) of subjects had achieved improvement by 3 weeks after PE therapy, with 55.6% (5/9) minimal improvement and 33.3% (3/9) moderate improvement. There were statistically significant improvements between baseline and after PE therapy at 3 weeks on the core set measures: physician global activity, patient global activity, HAQ, manual muscle testing (MMT), extramuscular disease activity, and muscle enzymes activity including creatine kinase (CK), lactate dehydrogenase (LDH), aspartate transaminase (AST), except for alanine transaminase (ALT). Moreover, the chest CT showed regression of ground glass opacities and irregular linear opacities after PE therapy in four patients with interstitial lung disease. The MRI images of lower extremity in four patients showed reduction of muscle oedema after the therapy. Conclusion PE therapy is effective for refractory IIM patients with positive anti-SRP antibody. It should be considered as an alternative treatment for those patients who are resistant to the combined therapy of glucocorticoids and immunosuppressive agents.
To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody. Nine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE therapy at Ruijin Hospital from October 2017 to December 2020. The clinical manifestations, laboratory tests, chest CT and lower extremity MRI images before and after PE therapy were compared. The treatment response was evaluated by the 2016 ACR/EULAR myositis response criteria. A total of 88.9% (8/9) of subjects had achieved improvement by 3 weeks after PE therapy, with 55.6% (5/9) minimal improvement and 33.3% (3/9) moderate improvement. There were statistically significant improvements between baseline and after PE therapy at 3 weeks on the core set measures: physician global activity, patient global activity, HAQ, manual muscle testing (MMT), extramuscular disease activity, and muscle enzymes activity including creatine kinase (CK), lactate dehydrogenase (LDH), aspartate transaminase (AST), except for alanine transaminase (ALT). Moreover, the chest CT showed regression of ground glass opacities and irregular linear opacities after PE therapy in four patients with interstitial lung disease. The MRI images of lower extremity in four patients showed reduction of muscle oedema after the therapy. PE therapy is effective for refractory IIM patients with positive anti-SRP antibody. It should be considered as an alternative treatment for those patients who are resistant to the combined therapy of glucocorticoids and immunosuppressive agents.
Author Sun, Yue
Chi, Huihui
Liu, Honglei
Cheng, Xiaobing
Zhang, Hao
Ye, Junna
Su, Yutong
Zhou, Zhuochao
Liu, Tingting
Jia, Jinchao
Wang, Mengyan
Yang, Chengde
Hu, Qiongyi
Teng, Jialin
Author_xml – sequence: 1
  givenname: Hao
  surname: Zhang
  fullname: Zhang, Hao
– sequence: 2
  givenname: Yue
  surname: Sun
  fullname: Sun, Yue
– sequence: 3
  givenname: Honglei
  surname: Liu
  fullname: Liu, Honglei
– sequence: 4
  givenname: Xiaobing
  surname: Cheng
  fullname: Cheng, Xiaobing
– sequence: 5
  givenname: Junna
  surname: Ye
  fullname: Ye, Junna
– sequence: 6
  givenname: Qiongyi
  orcidid: 0000-0002-4825-5227
  surname: Hu
  fullname: Hu, Qiongyi
– sequence: 7
  givenname: Jinchao
  surname: Jia
  fullname: Jia, Jinchao
– sequence: 8
  givenname: Mengyan
  surname: Wang
  fullname: Wang, Mengyan
– sequence: 9
  givenname: Tingting
  surname: Liu
  fullname: Liu, Tingting
– sequence: 10
  givenname: Zhuochao
  surname: Zhou
  fullname: Zhou, Zhuochao
– sequence: 11
  givenname: Chengde
  surname: Yang
  fullname: Yang, Chengde
– sequence: 12
  givenname: Huihui
  orcidid: 0000-0001-9587-1180
  surname: Chi
  fullname: Chi, Huihui
– sequence: 13
  givenname: Jialin
  surname: Teng
  fullname: Teng, Jialin
– sequence: 14
  givenname: Yutong
  orcidid: 0000-0002-0358-8933
  surname: Su
  fullname: Su, Yutong
  email: suyt2015@163.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34508561$$D View this record in MEDLINE/PubMed
BookMark eNqNkU1v1DAQhi1URD_gH6DKx17StZ3v3qoKWqRK5QBna-KMNwbHDrajkn9PtrtFVS9wskd-nhl53lNy5LxDQj5ydslZm2_CgPMIyVu_XTY_EbpKtG_ICS8qkbE8F0d_76I4Jqcx_mCMlTxv3pHjvChZU1b8hCxfLcQRKP5WA7gt0jRggGmhxtGAOoBKPuwqbWHcjVuLcfETpGGhjyYNFFwyWTRbB3Y1lN86k4x3dIKQjLL4BHS-X64oUAURacRgML4nbzXYiB8O5xn5_vnTt5u77P7h9svN9X2m8qJOme7qnrdNhYwjiEq1rBY9X9-KWkPZ6hr7nmvgZdn1wHmrG4VQsVojtEroKj8jF_u-U_C_ZoxJjiYqtBYc-jlKUda8FUWT1yt6fkDnbsReTsGMEBb5vK4VuNoDKvgY1_1IZRLsvpsCGCs5k7ts5Mts5CGbVS5eyc_9_6Ft9pqfp_8z_gDcSK6z
CitedBy_id crossref_primary_10_1007_s10067_022_06437_z
crossref_primary_10_1016_j_biopha_2022_113936
crossref_primary_10_1016_j_jaut_2024_103286
crossref_primary_10_1002_jca_21968
crossref_primary_10_1007_s11910_024_01337_y
crossref_primary_10_1002_cti2_1525
crossref_primary_10_3390_jpm14050461
Cites_doi 10.1002/mus.20693
10.1001/archneur.1981.00510090038003
10.1002/art.20349
10.1093/rheumatology/kez357
10.3389/fmed.2019.00239
10.1097/00001648-199001000-00010
10.1073/pnas.83.24.9507
10.1016/j.transci.2015.07.005
10.1186/s13023-015-0277-y
10.1136/annrheumdis-2018-213518
10.1093/rheumatology/keaa123
10.1001/jamaneurol.2015.1207
10.1136/annrheumdis-2016-210198
10.1056/NEJM197502132920706
10.1136/annrheumdis-2017-211400
10.1056/NEJM199205213262102
10.1093/rheumatology/keu436
10.1136/jnnp-2016-313166
ContentType Journal Article
Copyright The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021
The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Copyright_xml – notice: The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021
– notice: The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
DBID AAYXX
CITATION
NPM
7X8
DOI 10.1093/rheumatology/keab629
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1462-0332
EndPage 2630
ExternalDocumentID 34508561
10_1093_rheumatology_keab629
10.1093/rheumatology/keab629
Genre Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 81801600
– fundername: Shanghai Sailing Program
  grantid: 18YF1414500
GroupedDBID ---
-E4
.2P
.GJ
.I3
.XZ
.ZR
08P
0R~
18M
1TH
29P
2WC
354
3O-
4.4
48X
53G
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAGKA
AAJKP
AAJQQ
AAMDB
AAMVS
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNGD
ABNHQ
ABNKS
ABOCM
ABPTD
ABQLI
ABQNK
ABQTQ
ABVGC
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACPRK
ACUFI
ACUKT
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGZP
ADHKW
ADHZD
ADIPN
ADMTO
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEHUL
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFNX
AFFZL
AFIYH
AFOFC
AFXAL
AGINJ
AGKEF
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJEEA
AJNCP
AKWXX
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
AQDSO
ATGXG
ATTQO
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CAG
CDBKE
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBD
EBS
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HVGLF
HW0
HZ~
IOX
J21
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
M49
MHKGH
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBH
OCZFY
ODMLO
OHH
OJQWA
OJZSN
OPAEJ
OVD
OWPYF
O~Y
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
RIG
RNI
ROL
ROX
RUSNO
RW1
RXO
RZF
RZO
SV3
TCURE
TEORI
TJX
TMA
TR2
VVN
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZGI
ZKX
ZY1
~91
AAYXX
AHGBF
AJBYB
CITATION
ADJQC
ADRIX
AFXEN
NPM
OK1
RHF
7X8
ID FETCH-LOGICAL-c347t-fb7d1986e01ea26c9072d1c3447fa59f7edd1fa155bda119f8cea607fea9c2f63
ISSN 1462-0324
1462-0332
IngestDate Wed Oct 01 14:34:40 EDT 2025
Wed Feb 19 02:25:46 EST 2025
Wed Oct 01 04:43:18 EDT 2025
Thu Apr 24 22:51:11 EDT 2025
Wed Apr 02 07:04:32 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords idiopathic inflammatory myopathy
treatment
plasma exchange therapy
anti-SRP antibody
Language English
License This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c347t-fb7d1986e01ea26c9072d1c3447fa59f7edd1fa155bda119f8cea607fea9c2f63
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-4825-5227
0000-0001-9587-1180
0000-0002-0358-8933
PMID 34508561
PQID 2571924837
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_2571924837
pubmed_primary_34508561
crossref_citationtrail_10_1093_rheumatology_keab629
crossref_primary_10_1093_rheumatology_keab629
oup_primary_10_1093_rheumatology_keab629
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-05-30
PublicationDateYYYYMMDD 2022-05-30
PublicationDate_xml – month: 05
  year: 2022
  text: 2022-05-30
  day: 30
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Rheumatology (Oxford, England)
PublicationTitleAlternate Rheumatology (Oxford)
PublicationYear 2022
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Pinal-Fernandez (2022060107564816500_keab629-B10) 2017; 76
Ning (2022060107564816500_keab629-B18) 2019; 6
Aggarwal (2022060107564816500_keab629-B20) 2015; 54
Abe (2022060107564816500_keab629-B17) 2020; 59
Bohan (2022060107564816500_keab629-B6) 1975; 292
Cozzi (2022060107564816500_keab629-B16) 2015; 53
Rothman (2022060107564816500_keab629-B9) 1990; 1
Watanabe (2022060107564816500_keab629-B11) 2016; 87
Kassardjian (2022060107564816500_keab629-B4) 2015; 72
Suzuki (2022060107564816500_keab629-B3) 2015; 10
Dimitri (2022060107564816500_keab629-B2) 2007; 35
Cherin (2022060107564816500_keab629-B15) 1995; 13
Herson (2022060107564816500_keab629-B14) 1989; 140
Aggarwal (2022060107564816500_keab629-B8) 2017; 76
Rider (2022060107564816500_keab629-B7) 2004; 50
Reeves (2022060107564816500_keab629-B1) 1986; 83
Shirakashi (2022060107564816500_keab629-B5) 2020; 59
Bergua (2022060107564816500_keab629-B19) 2019; 78
Miller (2022060107564816500_keab629-B12) 1992; 326
Dau (2022060107564816500_keab629-B13) 1981; 38
References_xml – volume: 35
  start-page: 389
  year: 2007
  ident: 2022060107564816500_keab629-B2
  article-title: Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology
  publication-title: Muscle Nerve
  doi: 10.1002/mus.20693
– volume: 13
  start-page: 270
  year: 1995
  ident: 2022060107564816500_keab629-B15
  article-title: Plasma exchange in polymyositis and dermatomyositis: a multicenter study of 57 cases
  publication-title: Clin Exp Rheumatol
– volume: 38
  start-page: 544
  year: 1981
  ident: 2022060107564816500_keab629-B13
  article-title: Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients
  publication-title: Arch Neurol
  doi: 10.1001/archneur.1981.00510090038003
– volume: 50
  start-page: 2281
  year: 2004
  ident: 2022060107564816500_keab629-B7
  article-title: International consensus on preliminary definitions of improvement in adult and juvenile myositis
  publication-title: Arthritis Rheum
  doi: 10.1002/art.20349
– volume: 59
  start-page: 767
  year: 2020
  ident: 2022060107564816500_keab629-B17
  article-title: Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/kez357
– volume: 6
  start-page: 239
  year: 2019
  ident: 2022060107564816500_keab629-B18
  article-title: Efficiency of therapeutic plasma-exchange in acute interstitial lung disease, associated with polymyositis/dermatomyositis resistant to glucocorticoids and immunosuppressive drugs: a retrospective study
  publication-title: Front Med (Lausanne)
  doi: 10.3389/fmed.2019.00239
– volume: 1
  start-page: 43
  year: 1990
  ident: 2022060107564816500_keab629-B9
  article-title: No adjustments are needed for multiple comparisons
  publication-title: Epidemiology
  doi: 10.1097/00001648-199001000-00010
– volume: 140
  start-page: 453
  year: 1989
  ident: 2022060107564816500_keab629-B14
  article-title: Plasma exchange in dermatomyositis and polymyositis. Retrospective study of 38 cases of plasma exchange
  publication-title: Ann Med Interne
– volume: 83
  start-page: 9507
  year: 1986
  ident: 2022060107564816500_keab629-B1
  article-title: Human autoantibodies reactive with the signal-recognition particle
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.83.24.9507
– volume: 53
  start-page: 368
  year: 2015
  ident: 2022060107564816500_keab629-B16
  article-title: Plasma-exchange as a “rescue therapy” for dermato/polymyositis in acute phase. Experience in three young patients
  publication-title: Transfus Apher Sci
  doi: 10.1016/j.transci.2015.07.005
– volume: 10
  start-page: 61
  year: 2015
  ident: 2022060107564816500_keab629-B3
  article-title: Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients
  publication-title: Orphanet J Rare Dis
  doi: 10.1186/s13023-015-0277-y
– volume: 78
  start-page: 131
  year: 2019
  ident: 2022060107564816500_keab629-B19
  article-title: In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2018-213518
– volume: 59
  start-page: 3284
  year: 2020
  ident: 2022060107564816500_keab629-B5
  article-title: Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/keaa123
– volume: 72
  start-page: 996
  year: 2015
  ident: 2022060107564816500_keab629-B4
  article-title: Clinical features and treatment outcomes of necrotizing autoimmune myopathy
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2015.1207
– volume: 76
  start-page: 681
  year: 2017
  ident: 2022060107564816500_keab629-B10
  article-title: Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2016-210198
– volume: 292
  start-page: 344
  year: 1975
  ident: 2022060107564816500_keab629-B6
  article-title: Polymyositis and dermatomyositis (first of two parts)
  publication-title: N Engl J Med
  doi: 10.1056/NEJM197502132920706
– volume: 76
  start-page: 792
  year: 2017
  ident: 2022060107564816500_keab629-B8
  article-title: 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2017-211400
– volume: 326
  start-page: 1380
  year: 1992
  ident: 2022060107564816500_keab629-B12
  article-title: Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis
  publication-title: N Engl J Med
  doi: 10.1056/NEJM199205213262102
– volume: 54
  start-page: 1194
  year: 2015
  ident: 2022060107564816500_keab629-B20
  article-title: Anti-signal recognition particle autoantibody ELISA validation and clinical associations
  publication-title: Rheumatology
  doi: 10.1093/rheumatology/keu436
– volume: 87
  start-page: 1038
  year: 2016
  ident: 2022060107564816500_keab629-B11
  article-title: Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp-2016-313166
SSID ssj0005138
Score 2.430274
Snippet Abstract Objectives To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive...
To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition...
SourceID proquest
pubmed
crossref
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2625
Title Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series
URI https://www.ncbi.nlm.nih.gov/pubmed/34508561
https://www.proquest.com/docview/2571924837
Volume 61
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1462-0332
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0005138
  issn: 1462-0324
  databaseCode: KQ8
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1462-0332
  dateEnd: 20241102
  omitProxy: true
  ssIdentifier: ssj0005138
  issn: 1462-0324
  databaseCode: DIK
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1462-0332
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0005138
  issn: 1462-0324
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFA7jCuLL4t3xRgQfhKG7TdNJp76JKIO44sMujE8lt7pFp5XZFnb8Z_47Ty7tpK7ori9lGpLTSc_XnFzO-Q5CL3JqkJGpSJYijtK5IvDNSeOZI5SOpWRUmw39o49seZK-X81Xk8nPwGupa8WB_PHHuJL_0SqUgV5NlOwVNDsIhQL4DfqFK2gYrpfS8SeY-q75TJ-78N2ZC6bauhiVcmNT6Zi7EtS-dsfp621jkhBv-6C2toqMC4el9_euRI1hW3UPsxVE42ih-EyCyZuZnnnHw57Y-1R3RrxlczL0pee9x7xPERJsNwwb1Eve7A6k7ND3uRtA9qHqbJ0G2utq54KgXdtVxU3Y2pdwywJWu-a0PQ5G2ZRBGXXB0wc6LKOjodnxtHsIjsZZ5sKlvc1OmBN_wR44rqxN8Brg9qvmgvmOjwi4fzOMg7uiO6inRSin8FKuoesJGBSbNWQVeBcRm0R96GkftZnTw1DKoZcymhWNIi0vLHjsxOf4Ftr3Kxb82iHiNpro-g66ceR9Mu6irUMh7lGIPQpxVeMdCnGIQtyjEBsU4gCFOEAh7lGIexS-whwbDGKHwXvo5N3b4zfLyCf0iCRNszYqRaZIvmA6JponTOZxligiDelkyed5mWmlSMlhiisUJyQvF1JzFmel5rlMSkbvo726qfVDhFkeQyVFMx7LlMSCz4nKOdWEaKoElVNE-xdaSM92b5KufCv-pswpioZW3x3byz_qvwRdXbLq816hBYzg5liO17rpzgowmmYXZEGzKXrgND1IpCksoGCJ8-iKf-wxurn78J6gvXbT6acwe27FM4vTXwlg098
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+exchange+therapy+in+refractory+inflammatory+myopathy+with+anti-signal+recognition+particle+antibody%3A+a+case+series&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Zhang%2C+Hao&rft.au=Sun%2C+Yue&rft.au=Liu%2C+Honglei&rft.au=Cheng%2C+Xiaobing&rft.date=2022-05-30&rft.issn=1462-0324&rft.eissn=1462-0332&rft.volume=61&rft.issue=6&rft.spage=2625&rft.epage=2630&rft_id=info:doi/10.1093%2Frheumatology%2Fkeab629&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_rheumatology_keab629
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon